Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X

US10087242B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10087242-B2
Application numberUS-201414310667-A
CountryUS
Kind codeB2
Filing dateJun 20, 2014
Priority dateJun 5, 2007
Publication dateOct 2, 2018
Grant dateOct 2, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.

First claim

Opening claim text (preview).

The invention claimed is: 1. A saccharide derivative selected from the group consisting of: {(E)AB} n -WQ, WQ being bound to B in position 1, {CD(E)A} n -WQ, WQ being bound to A in position 1, {D(E)AB} n -WQ, WQ being bound to B in position 1, {(E)ABC} n -WQ, WQ being bound to C in position 1, {BCD(E)A} n -WQ, WQ being bound to A in position 1, {CD(E)ABC} n -WQ, WQ being bound to B in position 1, {D(E)ABC} n -WQ, WQ being bound to C in position 1, {(E)ABCD} n -WQ, WQ being bound to D in position 1, wherein A is a residue α-L-Rhap-(1) when bound to WQ, or a residue α-L-Rhap-(1,2) when bound to B or C, B is a residue α-L-Rhap-(1) when bound to WQ, or a residue α-L-Rhap-(1.3) when bound to A, C, or D, C is a residue α-L-Rhap-(1) or a residue [2-O-acetyl] α-L-Rhap-(1) when bound to WQ, or a residue α-L-Rhap-(1,3) or a residue [2-O-acetyl] α-L-Rhap-(1,3), when bound to A or D, D is a residue β-D-GlcNAcp-(1) when bound to WQ, or a residue β-D-GlcNAcp-(1,2) when bound to A, and E is a residue α-D-Glcp-(1,3), n is an integer between 1 and 10, W is an oxygen or sulfur atom and Q is an alkyl, an alkenyl, an acyl, or a donor group selected from the group consisting of the thioglycoside donors, trichloroacetimidate and trifluoroacetimidate. 2. A saccharide derivative selected from the group consisting of: {D(E)A} n -O-R-Z, O-R-Z being bound to A in position 1, {(E)AB} n -O-R-Z, O-R-Z being bound to B in position 1, {CD(E)A} n -O-R-Z, O-R-Z being bound to A in position 1, {D(E)AB} n -O-R-Z, O-R-Z being bound to B in position 1, {(E)ABC} n -O-R-Z, O-R-Z being bound to C in position 1, {BCD(E)A} n -O-R-Z, O-R-Z being bound to A in position 1, {CD(E)AB} n -O-R-Z, O-R-Z being bound to B in position 1, {D(E)ABC} n -O-R-Z, O-R-Z being bound to C in position 1, {(E)ABCD} n -O-R-Z, O-R-Z being bound to D in position 1, wherein A is a residue α-L-Rhap-(1) when bound to O-R-Z, or a residue α-L-Rhap-(1,2) when bound to B or C, B is a residue α-L-Rhap-1) when bound to O-R-Z, or a residue α-L-Rhap-(1,3) when bound to A, C or D, C is a residue α-L-Rhap-(1) or a residue [2-O-acetyl]α-L-Rhap-(1) when bound to O-R-Z, or a residue α-L-Rhap-(1,3) or a residue [2-O-acetyl]α-L-Rhap-(1,3) when bound to A or D, D is a residue β-D-GlcNAcp-(1) when bound to O-R-Z, or a residue β-D-GlcNAcp-(1,2) when bound to A, and E is a residue α-D-Glcp-(1,3), n is an integer between 1 and 10 Z is a functional group and R represents an alkyl group having from 1 to 12 carbon atoms. 3. A kit for diagnosis of an infection with Shigella flexneri of serotype 3a or X, wherein it comprises at least one saccharide as claimed in claim 1 .

Assignees

Inventors

Classifications

  • Antibacterial agents · CPC title

  • Immunostimulants · CPC title

  • General protective or antinoxious agents · CPC title

  • Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G) · CPC title

  • to nitrogen · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10087242B2 cover?
The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for syn…
Who is the assignee on this patent?
Pasteur Institut, Centre Nat Rech Scient, Univ Paris Descartes
What technology area does this patent fall under?
Primary CPC classification C07K16/1228. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).